According to reports from Business Standard, Arvaya Healthcare reported a standalone net loss of ₹0.89 crore for the quarter ended June 2026, representing a significant deterioration from the net loss of ₹0.25 crore recorded in the corresponding quarter of the previous financial year. The company's financial performance showed a 256% increase in losses year-on-year, indicating challenging operational conditions during the quarter. As per the latest financial data, the company's market capitalization stands at ₹529 crore with revenue of ₹0.10 crore and profit of -₹1.99 crore.
As reported by Business Standard, Arvaya Healthcare generated sales of ₹0.10 crore during the quarter ended June 2026, marking a substantial improvement from zero sales reported in the same quarter of the previous financial year. This revenue generation, while modest, represents the company's first recorded sales activity and provides a baseline for future comparisons. The latest financial data shows the company's revenue mix with revenue from operations accounting for 100% of total revenue.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) was negative at -810% during the quarter ended June 2026. The company's PBDT (Profit Before Depreciation and Tax) and PBT (Profit Before Tax) both stood at ₹0.89 crore, reflecting the same loss amount across these key profitability metrics. These operational metrics indicate significant challenges in the company's core business operations during the quarter. The operating profit margin has shown a consistent decline over recent years, with the company reporting -60.00% in March 2025 and -90.91% in March 2026.
As per the latest market data, Arvaya Healthcare is trading at 9.13 times its book value, indicating a premium valuation despite operational challenges. The company's promoter holding stands at 30.6%, which is relatively low compared to industry standards. The stock is trading at 9.31 times its book value with a low interest coverage ratio, suggesting potential financial leverage concerns. The company's return on equity (ROE) over the last 3 years stands at -4.99%, indicating negative profitability and challenging capital efficiency.
